Literature DB >> 16232098

Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.

Crystale Purvis Cooper1, Mona Saraiya, Teresa Abend McLean, Judy Hannan, Jaime M Liesmann, Shyanika Wijesinha Rose, Herschel W Lawson.   

Abstract

The National Breast and Cervical Cancer Early Detection Program (NBCCEDP), administered by the Centers for Disease Control and Prevention (CDC), provides breast and cervical cancer screening to low-income women who are uninsured or underinsured. For women with three consecutive annual Pap tests with normal findings, the NBCCEDP supports extending the screening interval to every 3 years. Thirteen telephone focus groups were conducted with physician providers in 17 states and the District of Columbia to investigate familiarity with NBCCEDP's triennial Pap test policy, the Pap test intervals actually used, and the factors influencing screening interval selection. No participants were familiar with NBCCEDP's triennial Pap test policy, and none reported routinely extending the screening interval after three consecutive annual Pap tests with normal findings. Two patterns of screening interval use were reported: annual screeners continued performing yearly Pap tests, and selective extended screeners offered an extended interval to select patients. Annual and selective extended screeners reported that both unique and common factors influenced the screening intervals they used. The NBCCEDP has established its cancer screening priorities to focus limited resources on the goal of providing services to eligible women who have rarely or never been screened. Increased efforts are needed to educate physicians about the science supporting an extended Pap screening interval and overcome the barriers associated with its adoption.

Entities:  

Mesh:

Year:  2005        PMID: 16232098     DOI: 10.1089/jwh.2005.14.670

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  10 in total

1.  Too much of a good thing?

Authors:  Brenda E Sirovich
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

2.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries.

Authors:  Dik Habbema; Inge M C M De Kok; Martin L Brown
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

3.  Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.

Authors:  Michelle I Silver; Anne F Rositch; Darcy F Phelan-Emrick; Patti E Gravitt
Journal:  Cancer Causes Control       Date:  2017-11-09       Impact factor: 2.506

4.  Acceptable and Preferred Cervical Cancer Screening Intervals Among U.S. Women.

Authors:  Crystale Purvis Cooper; Mona Saraiya; George F Sawaya
Journal:  Am J Prev Med       Date:  2015-07-02       Impact factor: 5.043

5.  Cancer screening practices among physicians in the national breast and cervical cancer early detection program.

Authors:  Vicki B Benard; Mona S Saraiya; Ashwini Soman; Katherine B Roland; K Robin Yabroff; Jackie Miller
Journal:  J Womens Health (Larchmt)       Date:  2011-07-20       Impact factor: 2.681

6.  Current status of cervical cancer and HPV infection in Korea.

Authors:  Young-Tak Kim
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

Review 7.  The impact of human papillomavirus vaccination on cervical cancer prevention efforts.

Authors:  L Stewart Massad; Mark Einstein; Evan Myers; Cosette M Wheeler; Nicolas Wentzensen; Diane Solomon
Journal:  Gynecol Oncol       Date:  2009-05-01       Impact factor: 5.482

8.  Human Papilloma Virus Genotype Distribution in Cervical lesions in Zanjan, Iran

Authors:  Shahrzad Ahmadi; Hossein Goudarzi; Ahmad Jalilvand; Abdolreza Esmaeilzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

9.  Market survey predictions on the future of US Pap testing.

Authors:  R Marshall Austin; Barbara Benstein; Joel Bentz; Sandra Bigner; Gregory G Freund; Gregory La Rocco; Ibrahim Ramzy; Lynnette Savaloja; Vinod B Shidham
Journal:  Cytojournal       Date:  2009-09-18       Impact factor: 2.091

Review 10.  Applying a gender lens on human papillomavirus infection: cervical cancer screening, HPV DNA testing, and HPV vaccination.

Authors:  Ivan Branković; Petra Verdonk; Ineke Klinge
Journal:  Int J Equity Health       Date:  2013-02-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.